Content Type: Commentary & Opinion

Inflation Reduction Act and US Drug Pricing

March 16, 2026

Op-Ed: Increase Transparency at the FDA: We Need Sunlight to Fight the Pandemic

March 16, 2026

Op-Ed: Do Large Pharma Companies Provide Drug Development Innovation? Our Analysis Says No

March 16, 2026

Op-Ed: Searching for an Effective COVID-19 Treatment: Promise and Peril

March 16, 2026

Op-Ed: Prevent a Legal Catch-22 That Could Push Thousands of Generic Drugs Off the Market

March 16, 2026

Op-Ed: Makena Is Just the Latest in Accelerated Approval Mayhem

March 16, 2026

Op-Ed: Letting the Government Negotiate Drug Prices Won’t Hurt Innovation

March 16, 2026

Efficacy of the Priority Review Voucher Program (Reply)

March 16, 2026

The Fight Against Multidrug-Resistant Bacteria (Reply)

March 16, 2026

Delayed Generic Market Saturation After Patent Expiration—A Billion-Dollar Problem

March 16, 2026

Institutionalizing Misinformation—the Dietary Supplement Listing Act of 2022

March 16, 2026

Recalibrating Privacy Protections to Promote Patient Engagement

March 16, 2026